Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Sanofi-Aventis S.A. ADR (NQ: SNY )

57.65 UNCHANGED
Streaming Delayed Price Updated: 4:00 PM EDT, Sep 27, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Sanofi-Aventis S.A. ADR

< Previous 1 2 3 4 5 6 7 8 9
...
28 29 Next >
Week In Review: Zenas Raises $259 Million In IPO
It was a quiet week for biotech news in the Chinese market. Here is a brief overview of the notable events that occurred during this time. Zenas BioPharma staged a rare US biopharma IPO worth $259... 
Via Talk Markets
Topics Initial Public Offering
Exposures Securities Market
FDA Approves Regeneron/Sanofi's Blockbuster Dupixent For Smoker's Lung Disease
The FDA approved Regeneron and Sanofi's Dupixent as an add-on treatment for inadequately controlled COPD, demonstrating significant reductions in exacerbations and improved lung function in Phase 3... 
Via Benzinga
Exposures Product Safety
Regeneron And Sanofi Snag Their $6 Billion-Potential COPD Approval For Dupixent
The FDA signed off on Regeneron and Sanofi's Dupixent for patients with uncontrolled COPD. 
Via Investor's Business Daily
Exposures Product Safety
Amgen's Rocatinlimab Has Commercial Potential Despite Competitive Landscape, Says Goldman Sachs
Amgen releases Phase 3 trial data for rocatinlimab and Uplizna, with analysts projecting strong sales despite competition in the atopic dermatitis and myasthenia gravis markets. Attention shifts to... 
Via Benzinga
Amgen's Rocatinlimab Data Beats Placebo In Atopic Dermatitis Trial, But Analyst Says Data Raises Concerns Amid Competitive Market
Amgen reports mixed results from Phase 3 trials, with rocatinlimab showing moderate success in atopic dermatitis and Uplizna outperforming expectations in myasthenia gravis, offering less frequent... 
Via Benzinga
NASDAQ:SNY may be ready to breakout.
Will SANOFI-ADR breakout? 
Via Chartmill
Private Equity Firms Circle Sanofi's Consumer Health Business Amid Potential Spinoff
Sanofi plans to spin off its consumer healthcare division, which could be valued at over $16.8 billion. Private equity firms are bidding for the unit, with the spinoff expected by Q4 2024. Banks... 
Via Benzinga
Sanofi Injects $27M In Neurology Drug Developer Ventyx Biosciences
Sanofi invests $27 million in Ventyx Biosciences at $3.8243 per share. The investment will fund VTX3232 trials for Parkinson's disease. 
Via Benzinga
Sanofi's Sarclisa Secures FDA Approval For First-Line Multiple Myeloma, Marking Its Third US Approval
The FDA approved Sanofi's Sarclisa (isatuximab) in combination with VRd as a first-line treatment for newly diagnosed multiple myeloma patients ineligible for stem cell transplants. Sarclisa is the... 
Via Benzinga
Exposures Product Safety
US Federal Trade Commission Sues CVS Health, Cigna, UnitedHealth's Pharmacy Benefit Managers For Inflating Insulin Prices
FTC files a complaint against CVS, Cigna, and UnitedHealth's PBMs, accusing them of inflating insulin prices through a rebate-driven system. The case aims to address unfair practices and improve access... 
Via Benzinga
Topics Lawsuit
Exposures Financial Legal
Sanofi's Tolebrutinib Delays Disability Progression In Patients With Multiple Sclerosis, Data Shows
Sanofi reports positive phase 3 HERCULES study data for tolebrutinib in non-relapsing secondary progressive multiple sclerosis, showing a 31% delay in disability progression. Study also revealed... 
Via Benzinga
Novartis' Multiple Sclerosis Drug Data Shows Most Patients Remain With No Disability Progression For Up To Six Years
Novartis' new data for Kesimpta showed reduced disability progression in relapsing multiple sclerosis patients. Continuous Kesimpta treatment led to better outcomes compared to those who switched from... 
Via Benzinga
Time To Invest And Or Trade In Bio-Tech Stocks?
Biotechnology stocks and biotech exchange-traded funds ETFs once played a significant role in growth equity rallies, but today it seems like those days are in the past. Will an interest rate cut help... 
Via Talk Markets
Topics ETFs
Should You Buy Novavax Stock After This Regulatory Win?
The biotech continues to earn important wins, but is it enough? 
Via The Motley Fool
Sanofi, Regeneron Drug Dupixent Shows Successful Treatment Of Patients With Inflammatory Skin Disease
Regeneron and Sanofi's Dupixent achieves positive Phase 3 results for chronic spontaneous urticaria, meeting key endpoints. 
Via Benzinga
Despite its impressive fundamentals, NASDAQ:SNY remains undervalued.
When you look at SANOFI-ADR (NASDAQ:SNY), it's hard to ignore the strong fundamentals, especially considering its likely undervaluation. 
Via Chartmill
FDA Battles Backlog of Drug Factory Inspections Since COVID-19
FDA faces inspection backlog with serious public health implications, as critical drug manufacturing plants remain unchecked. 
Via Benzinga
Exposures Product Safety
Why Sanofi Stock Was Robustly Healthy Today
Investors found something to like about the company's recent round of clinical trials for a key pipeline medication. 
Via The Motley Fool
Sanofi Still Bets On Multiple Sclerosis Med Tolebrutinib Despite The Investigational Drug Fell Short In 2 Of 3 Phase 3 Trials
Sanofi's phase 3 HERCULES study data shows tolebrutinib met the primary endpoint in delaying disability progression in non-relapsing secondary progressive multiple sclerosis. 
Via Benzinga
European Stocks Little Moved On Labor Day, German DAX Mark Record Close, Natural Gas Futures Rise: What's Driving Markets Monday?
Global markets started September cautiously, with thin trading volumes as U.S. stock markets were closed for the Labor Day holiday. 
Via Benzinga
Topics Energy
Exposures Fossil Fuels
Governments Suing Pharmacy Benefit Managers Over Insulin Prices Have Long Benefited From Their Rebates
State and local governments suing PBMs and drug companies over insulin prices have long benefited from the same rebate system they now criticize, leaving patients burdened by high costs and limited... 
Via Benzinga
Wall Street Predicts That This Stock Could Skyrocket by 65%: Time to Buy?
Don't be too quick to jump on the Wall Street bandwagon. 
Via The Motley Fool
ARS Pharmaceuticals 'Neffy Uniquely Positioned With Potential To Change Allergy Treatment Paradigm For First Time In 40 years:' Analyst
"FDA recently approved ARS Pharmaceuticals' neffy nasal spray for emergency allergic reactions, offering an alternative to epinephrine autoinjectors like EpiPen. Cantor sees strong market potential and... 
Via Benzinga
Novavax Stock Rocketed This Year, But Challenges Persist. Is It A Buy Or A Sell?
Its 12-month relative strength performance is impressive, but Novavax now faces resistance. 
Via Investor's Business Daily
NASDAQ:SNY is probably undervalued for the fundamentals it is displaying.
SANOFI-ADR (NASDAQ:SNY) appears to be flying under the radar despite its strong fundamentals. 
Via Chartmill
Florida Ruling Upholds GSK's Stance On Once Popular Heart Burn Drug Zantac Not Being Associated With Cancer Risk
A Florida State Court sided with GSK, dismissing expert testimonies that linked ranitidine to prostate cancer, reflecting a broader scientific consensus that there is no consistent evidence supporting... 
Via Benzinga
3 Biotech Stocks to Buy on the Dip: August 2024
These are three of the best biotech stocks to buy on the dip due to their strong fundamentals and market positioning. 
Via InvestorPlace
AnaptysBio Hits Five-Year High After Sanofi Takes A Stake In $100 Million Offering
The company is working on treatments for immunological diseases, including eczema and rheumatoid arthritis. 
Via Investor's Business Daily
FDA Approves ARS Pharma's Once Rejected Neffy Nasal Spray Alternative To EpiPen For Emergency Allergy Treatment
FDA approves ARS Pharmaceuticals' Neffy, the first nasal spray for treating severe allergic reactions and anaphylaxis. This new option offers a non-injection alternative to epinephrine autoinjectors,... 
Via Benzinga
Exposures Product Safety
COVID-19 Vaccine Maker Novavax Trims Annual Outlook As Q2 Sales Take A Hit
Novavax reported Q2 2024 revenue of $415 million, missing estimates, with net income rising to $162 million. EPS increased to $0.99, below expectations. The company revised its 2024 revenue guidance to... 
Via Benzinga
Exposures COVID-19
< Previous 1 2 3 4 5 6 7 8 9
...
28 29 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.